Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$266.11+0.61%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALNY
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||||||
| Revenues | 4,804.2 | 3,713.9 | 2,248.2 | 1,828.3 | 1,037.4 | 844.3 | 492.9 | 219.8 | 74.9 | — | — | — | — | — | — | — | 100.0 |
| Total Revenues | — | — | — | — | 1,037.4 | 844.3 | 492.9 | — | — | — | — | — | — | — | — | — | 100.0 |
| Cost of Revenues | 970.7 | 677.2 | 306.5 | 268.2 | 140.2 | 115.0 | 74.2 | 25.1 | 1.8 | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||||||||
| Selling, General & Admin | 1,317.9 | 1,210.7 | 975.5 | 795.6 | 770.7 | 620.6 | 588.4 | 479.0 | 382.4 | — | — | — | — | — | — | — | — |
| R&D Expenses | 1,509.0 | 1,319.8 | 1,126.2 | 1,004.4 | 883.0 | 792.2 | 654.8 | 655.1 | 505.4 | 390.6 | 382.4 | 276.5 | 190.2 | 113.0 | 86.6 | 99.3 | 106.4 |
| Operating Income | 999.8 | 501.6 | (176.9) | (282.2) | (785.1) | (708.7) | (828.4) | (939.4) | (814.7) | (500.1) | (424.6) | (296.0) | (405.0) | (92.9) | (129.5) | (54.8) | (44.1) |
| Earnings from Continuing Operations | |||||||||||||||||
| Interest Expense | — | 252.6 | 141.9 | 121.2 | 156.0 | 143.0 | 84.5 | — | — | — | — | — | — | — | — | — | 0.9 |
| Interest & Investment Income | 110.1 | 111.5 | 122.0 | 95.6 | 24.8 | 1.6 | 11.8 | — | — | — | — | — | — | — | 1.0 | 1.2 | 2.3 |
| Net Interest Expenses | — | — | — | 25.7 | 131.2 | 141.4 | 72.7 | — | — | — | — | — | — | — | — | — | (1.4) |
| Other Non-Operating Income / Expenses | (233.5) | (178.4) | (200.5) | (151.3) | (341.9) | (143.5) | (27.2) | 54.2 | 54.0 | 9.2 | 14.5 | 5.9 | 4.4 | 1.0 | 12.9 | (2.8) | 1.1 |
| EBT, Incl. Unusual Items | 766.3 | 323.2 | (377.4) | (433.5) | (1,127.0) | (852.1) | (855.6) | (885.3) | (760.7) | (490.9) | (410.1) | (290.1) | (400.6) | (91.9) | (116.6) | (57.6) | (43.0) |
| Income Tax Expense | (8.4) | 9.4 | (99.2) | 6.7 | 4.2 | 0.7 | 2.7 | 0.9 | 0.8 | — | — | 0.0 | (40.2) | (2.7) | (10.6) | 0.5 | 0.5 |
| Net Income | |||||||||||||||||
| Net Income | 774.7 | 313.7 | (278.2) | (440.2) | (1,131.2) | (852.8) | (858.3) | (886.1) | (761.5) | (490.9) | (410.1) | (290.1) | (360.4) | (89.2) | (106.0) | (57.6) | (43.5) |
| Per Share | |||||||||||||||||
| Basic EPS | 5.80 | 2.39 | (2.18) | (3.52) | (9.30) | (7.20) | (7.46) | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 5.60 | 2.33 | (2.18) | (3.52) | (9.30) | (7.20) | (7.46) | — | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 34.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 133.6 | 131.0 | 127.7 | 124.9 | 121.7 | 118.5 | 115.0 | — | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 138.3 | 134.7 | 127.7 | 124.9 | 121.7 | 118.5 | 115.0 | — | — | — | — | — | — | — | — | — | — |
| Supplemental | |||||||||||||||||
| EBITDA | — | 557.2 | (120.2) | (228.1) | (740.6) | (661.1) | (793.7) | (922.3) | (799.4) | (486.7) | (409.5) | (277.0) | (393.1) | (82.7) | (120.4) | (49.7) | (39.1) |
| EBIT | 999.8 | 501.6 | (176.9) | (282.2) | (785.1) | (708.7) | (828.4) | (939.4) | (814.7) | (500.1) | (424.6) | (296.0) | (405.0) | (92.9) | (129.5) | (54.8) | (44.1) |
| Effective Tax Rate | -1.1% | — | — | -1.6% | -0.4% | -0.1% | -0.3% | -0.1% | -0.1% | — | — | 0.0% | 10.0% | 2.9% | 9.1% | -0.9% | -1.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.